COVID-19-associated coagulopathy: Difference between revisions
Jump to navigation
Jump to search
(→Age) |
|||
| Line 16: | Line 16: | ||
==Historical Perspective== | ==Historical Perspective== | ||
* The etiological agent is [[SARS-CoV-2]], named for the similarity of its symptoms to those induced by the [[severe acute respiratory syndrome]], causing [[coronavirus]] disease 2019 ([[COVID-19]]), is a [[virus]] identified as the cause of an outbreak of [[respiratory illness]] first detected in Wuhan, China. | * The etiological agent is [[SARS-CoV-2]], named for the similarity of its symptoms to those induced by the [[severe acute respiratory syndrome]], causing [[coronavirus]] disease 2019 ([[COVID-19]]), is a [[virus]] identified as the cause of an outbreak of [[respiratory illness]] first detected in Wuhan, China. | ||
*The growing number of [[patients]] however, suggest that human-to-human transmission is actively occurring. | *The growing number of [[patients]] however, suggest that human-to-human transmission is actively occurring. | ||
*The [[outbreak]] was declared a Public Health Emergency of International Concern on 30 January 2020. | *The [[outbreak]] was declared a Public Health Emergency of International Concern on 30 January 2020. | ||
*On March 12, 2020, the [[World Health Organization]] declared the [[COVID-19]] outbreak a [[pandemic]]. | *On March 12, 2020, the [[World Health Organization]] declared the [[COVID-19]] outbreak a [[pandemic]]. | ||
| Line 25: | Line 25: | ||
* There is no established system for the classification of the [[hypercoagulability]] seen in [[COVID-19]]. | * There is no established system for the classification of the [[hypercoagulability]] seen in [[COVID-19]]. | ||
* The [[coagulopathy]] may be classified according to the type of vessels and organs involved into: | * The [[coagulopathy]] may be classified according to the type of vessels and organs involved into: | ||
**[[Venous thrombosis]] | **[[Venous thrombosis]] | ||
**[[Arterial thrombosis]] | **[[Arterial thrombosis]] | ||
| Line 34: | Line 34: | ||
==Pathophysiology== | ==Pathophysiology== | ||
* [[COVID-19]] induces a [[Hypercoagulable state|hypercoagulable]] state in the body. An increased risk of [[mortality]] has been noted in patient’s with [[coagulopathy]] in COVID-19. It is thought that the [[coagulopathy]] in COVID-19 is the result of:<ref name="pmid32415579" / | * [[COVID-19]] induces a [[Hypercoagulable state|hypercoagulable]] state in the body. An increased risk of [[mortality]] has been noted in patient’s with [[coagulopathy]] in COVID-19. It is thought that the [[coagulopathy]] in COVID-19 is the result of:<ref name="pmid32415579" /> | ||
**[[Virchow's triad|Virchow]]’s triad | **[[Virchow's triad|Virchow]]’s triad | ||
** Vascular [[Endothelium|endothelial]] damage | ** Vascular [[Endothelium|endothelial]] damage | ||
**Endothelitis- direct invasion of endothelial cells by SARS-CoV-2 which exposes the [[vWF]] associated with a massive release of [[vWF]], eventually activating the [[coagulation cascade]]. | **Endothelitis- direct invasion of endothelial cells by SARS-CoV-2 which exposes the [[vWF]] associated with a massive release of [[vWF]], eventually activating the [[coagulation cascade]]. | ||
**[[Complement system|Complement]] mediated damage to pericytes | **[[Complement system|Complement]] mediated damage to pericytes | ||
**Pro-inflammatory [[Cytokine|cytokines]]- IL-1, IL-6, and TNF- α, that activate the [[Coagulation cascade|coagulation]] pathway and the fibrinolytic system. | **Pro-inflammatory [[Cytokine|cytokines]]- IL-1, IL-6, and TNF- α, that activate the [[Coagulation cascade|coagulation]] pathway and the fibrinolytic system. | ||
*[[Stasis (medicine)|Stasis]]- Prolonged hospital admissions causing immobilization of the patient | *[[Stasis (medicine)|Stasis]]- Prolonged hospital admissions causing immobilization of the patient | ||
*[[Hypercoagulabe]] state- Evidenced by elevated [[fibrinogen]], prothrombotic factors and [[Hyperviscosity syndrome|hyperviscosity]] | *[[Hypercoagulabe]] state- Evidenced by elevated [[fibrinogen]], prothrombotic factors and [[Hyperviscosity syndrome|hyperviscosity]] | ||
*Some patients have been found to have [[Lupus anticoagulant]] ([[Anti-cardiolipin antibodies|anti-cardiolipin]]) and anti-β2GP1 [[antibodies]] that may be contributory. | *Some patients have been found to have [[Lupus anticoagulant]] ([[Anti-cardiolipin antibodies|anti-cardiolipin]]) and anti-β2GP1 [[antibodies]] that may be contributory. | ||
==Causes== | ==Causes== | ||
| Line 60: | Line 60: | ||
** [[Antiphospholipid antibody syndrome]] | ** [[Antiphospholipid antibody syndrome]] | ||
* The main feature of COVID-19 coagulopathy is [[thrombosis]] while the acute phase of [[DIC]] presents with [[bleeding]]: | * The main feature of COVID-19 coagulopathy is [[thrombosis]] while the acute phase of [[DIC]] presents with [[bleeding]]: | ||
*Similar laboratory findings are marked increase in [[D-dimer]] and normal/slightly low [[platelets]] and prolonged [[Prothrombin time|PT.]] | *Similar laboratory findings are marked increase in [[D-dimer]] and normal/slightly low [[platelets]] and prolonged [[Prothrombin time|PT.]] | ||
*Findings distinct in COVID 19 are high [[fibrinogen]] and high [[factor VIII]] activity | *Findings distinct in COVID 19 are high [[fibrinogen]] and high [[factor VIII]] activity | ||
*The scoring system of the [https://www.isth.org/ International Society on Thrombosis and Hemostasis] should be used to detect DIC ([[platelet]] count, PT, [[fibrinogen]], D‐dimer, [[antithrombin]] and [[protein C]] activity monitoring), but the diagnosis and subsequent treatment should be done clinically. | *The scoring system of the [https://www.isth.org/ International Society on Thrombosis and Hemostasis] should be used to detect DIC ([[platelet]] count, PT, [[fibrinogen]], D‐dimer, [[antithrombin]] and [[protein C]] activity monitoring), but the diagnosis and subsequent treatment should be done clinically. | ||
To view the differential diagnosis of COVID-19, [[COVID-19 differential diagnosis|click here]].<br /> | To view the differential diagnosis of COVID-19, [[COVID-19 differential diagnosis|click here]].<br /> | ||
| Line 72: | Line 72: | ||
===Incidence=== | ===Incidence=== | ||
* The incidence of venous [[thromboembolism]] in [[Intensive care unit|ICU]] patients with COVID-19 was analyzed in a study by Klok et al. | * The [[Incidence (epidemiology)|incidence]] of venous [[thromboembolism]] in [[Intensive care unit|ICU]] patients with COVID-19 was analyzed in a study by Klok et al. | ||
* It concluded that the cumulative [[incidence]] of acute [[pulmonary embolism]] ([[Pulmonary embolism|PE]]), [[deep vein thrombosis]] ([[Deep vein thrombosis|DVT]]), [[ischemic stroke]], [[ST elevation myocardial infarction|MI]], or systemic [[Arterial embolism|arterial embolism was 31%.]] | * It concluded that the cumulative [[incidence]] of acute [[pulmonary embolism]] ([[Pulmonary embolism|PE]]), [[deep vein thrombosis]] ([[Deep vein thrombosis|DVT]]), [[ischemic stroke]], [[ST elevation myocardial infarction|MI]], or systemic [[Arterial embolism|arterial embolism was 31%.]] | ||
* The incidence of most common [[Thrombosis|thrombotic]] complication was pulmonary embolism seen in 81% of patients. All these patients were on at least standard doses of thromboprophylaxis. <ref name="pmid32291094">{{cite journal| author=Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM | display-authors=etal| title=Incidence of thrombotic complications in critically ill ICU patients with COVID-19. | journal=Thromb Res | year= 2020 | volume= 191 | issue= | pages= 145-147 | pmid=32291094 | doi=10.1016/j.thromres.2020.04.013 | pmc=7146714 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32291094 }} </ref> | * The [[Incidence (epidemiology)|incidence]] of most common [[Thrombosis|thrombotic]] complication was [[pulmonary embolism]] seen in 81% of patients. All these patients were on at least standard doses of thromboprophylaxis. <ref name="pmid32291094">{{cite journal| author=Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM | display-authors=etal| title=Incidence of thrombotic complications in critically ill ICU patients with COVID-19. | journal=Thromb Res | year= 2020 | volume= 191 | issue= | pages= 145-147 | pmid=32291094 | doi=10.1016/j.thromres.2020.04.013 | pmc=7146714 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32291094 }} </ref> | ||
* The cumulative | * The cumulative [[Incidence (epidemiology)|incidence]] of [[Venous thromboembolism|venous thromboembolism (VTE)]] were 16% (95% CI, 10-22) at 7 days, 33% (95% CI, 23-43) at 14 days and 42% (95% CI 30-54) at 21 days. | ||
* Comparatively, the cumulative incidence of VTE was ''' | * Comparatively, the cumulative [[incidence]] of [[venous thromboembolism]] ([[Venous thromboembolism|VTE]]) was higher in the '''ICU''' patients - 26% (95% CI, 17-37) at 7 days, 47% (95% CI, 34-58) at 14 days and 59% (95% CI, 42-72) at 21 days) than on the floor. | ||
To view the epidemiology and demographics for COVID-19, [[COVID-19 epidemiology and demographics|click here]].<br /> | To view the epidemiology and demographics for COVID-19, [[COVID-19 epidemiology and demographics|click here]].<br /> | ||
| Line 94: | Line 94: | ||
==Risk Factors== | ==Risk Factors== | ||
Hypothesized risk factors for coagulopathy in COVID-19 pneumonia based on studies include | Hypothesized [[Risk factor|risk factors]] for [[coagulopathy]] in [[COVID-19]] [[pneumonia]] based on studies include: | ||
*[[Intensive care unit|ICU]] admission <ref name="pmid32291094">{{cite journal| author=Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM | display-authors=etal| title=Incidence of thrombotic complications in critically ill ICU patients with COVID-19. | journal=Thromb Res | year= 2020 | volume= 191 | issue= | pages= 145-147 | pmid=32291094 | doi=10.1016/j.thromres.2020.04.013 | pmc=7146714 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32291094 }} </ref> | *[[Intensive care unit|ICU]] admission <ref name="pmid32291094">{{cite journal| author=Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM | display-authors=etal| title=Incidence of thrombotic complications in critically ill ICU patients with COVID-19. | journal=Thromb Res | year= 2020 | volume= 191 | issue= | pages= 145-147 | pmid=32291094 | doi=10.1016/j.thromres.2020.04.013 | pmc=7146714 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32291094 }} </ref> | ||
* Age (> 40 years) | * Age (> 40 years) | ||
*[[Hypoxia]] | *[[Hypoxia]] | ||
Other general risk factors for VTE are | Other general [[Risk factor|risk factors]] for [[venous thromboembolism]] ([[Venous thromboembolism|VTE]]) are: | ||
* Male | * Male | ||
* Active [[cancer]] | * Active [[cancer]] | ||
* Recent major surgery | * Recent major [[surgery]] | ||
* High [[Body mass index|BMI]] ([[obesity]]) | * High [[Body mass index|BMI]] ([[obesity]]) | ||
* Prior [[Venous thromboembolism|VTE]] | * Prior [[Venous thromboembolism|VTE]] | ||
| Line 111: | Line 111: | ||
==Screening== | ==Screening== | ||
Routine [[Screening (medicine)|screening]] with [[imaging]] is not done as there is no evidence to indicate an improvement in clinical outcomes. Depending on the clinical state of the patient and suspicion for the development of [[Venous thromboembolism|VTE]] or [[Artery|arterial]] thrombi, repeat testing and further imaging investigations are done. | * Every patient with [[COVID-19]] infection admitted to the hospital should have a baseline of basic blood investigations such as | ||
**[[Complete blood count]] ([[Complete blood count|CBC]]) | |||
**[[Platelet count]] | |||
** Prothrombin Time ([[Prothrombin time|PT]]), [[Activated partial thromboplastin time]] (aPTT) | |||
**[[Fibrinogen]] | |||
**[[D-dimer]] | |||
**[[C-reactive protein]] | |||
* Routine [[Screening (medicine)|screening]] with [[imaging]] is not done as there is no evidence to indicate an improvement in clinical outcomes. | |||
* Depending on the clinical state of the patient and suspicion for the development of [[Venous thromboembolism|VTE]] or [[Artery|arterial]] thrombi, repeat testing and further imaging investigations are done. | |||
To view screening for COVID-19, [[COVID-19 screening|click here]].<br /> | To view screening for COVID-19, [[COVID-19 screening|click here]].<br /> | ||
| Line 130: | Line 132: | ||
===Complications=== | ===Complications=== | ||
*[[Thrombosis|Thrombotic]] complications : <ref name="pmid32415579">{{cite journal| author=Becker RC| title=COVID-19 update: Covid-19-associated coagulopathy. | journal=J Thromb Thrombolysis | year= 2020 | volume= | issue= | pages= | pmid=32415579 | doi=10.1007/s11239-020-02134-3 | pmc=7225095 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32415579 | *[[Thrombosis|Thrombotic]] complications : <ref name="pmid32415579">{{cite journal| author=Becker RC| title=COVID-19 update: Covid-19-associated coagulopathy. | journal=J Thromb Thrombolysis | year= 2020 | volume= | issue= | pages= | pmid=32415579 | doi=10.1007/s11239-020-02134-3 | pmc=7225095 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32415579 }} </ref> | ||
**[[Deep vein thrombosis|Deep Vein Thrombosis]] | **[[Deep vein thrombosis|Deep Vein Thrombosis]] | ||
**[[Pulmonary embolism|Pulmonary Embolism]] | **[[Pulmonary embolism|Pulmonary Embolism]] | ||
| Line 147: | Line 149: | ||
===Prognosis=== | ===Prognosis=== | ||
Prognosis depends on numerous factors- | Prognosis depends on numerous factors- | ||
* Increased [[D-dimer]] levels- poor prognosis | * Increased [[D-dimer]] levels- poor prognosis | ||
* Increased [[fibrin degradation product]] (FDP) levels <ref name="pmid32073213">{{cite journal| author=Tang N, Li D, Wang X, Sun Z| title=Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. | journal=J Thromb Haemost | year= 2020 | volume= 18 | issue= 4 | pages= 844-847 | pmid=32073213 | doi=10.1111/jth.14768 | pmc=7166509 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32073213 }} </ref> | * Increased [[fibrin degradation product]] (FDP) levels <ref name="pmid32073213">{{cite journal| author=Tang N, Li D, Wang X, Sun Z| title=Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. | journal=J Thromb Haemost | year= 2020 | volume= 18 | issue= 4 | pages= 844-847 | pmid=32073213 | doi=10.1111/jth.14768 | pmc=7166509 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32073213 }} </ref> | ||
*[[Intensive care unit|ICU]] admission | *[[Intensive care unit|ICU]] admission | ||
| Line 222: | Line 224: | ||
Laboratory findings consistent with the diagnosis of [[COVID-19]] associated [[coagulopathy]] include: | Laboratory findings consistent with the diagnosis of [[COVID-19]] associated [[coagulopathy]] include: | ||
* Coagulation testing- Pro-coagulant profile | * Coagulation testing- Pro-coagulant profile | ||
**[[Platelet]] Counts- Normal or increased | **[[Platelet]] Counts- Normal or increased | ||
**[[Prothrombin time]] (PT) and [[activated partial thromboplastin time]] (aPTT)- normal or slightly prolonged | **[[Prothrombin time]] (PT) and [[activated partial thromboplastin time]] (aPTT)- normal or slightly prolonged | ||
| Line 231: | Line 233: | ||
**[[Protein C]], [[Protein S]], [[Antithrombin III]] - slightly decreased | **[[Protein C]], [[Protein S]], [[Antithrombin III]] - slightly decreased | ||
[[TEGT|TEG]] findings: | [[TEGT|TEG]] findings: | ||
* Reaction time (R) - decreased | * Reaction time (R) - decreased | ||
| Line 261: | Line 263: | ||
===== CTPA and Ventilation Perfusion(V/Q) Scan ===== | ===== CTPA and Ventilation Perfusion(V/Q) Scan ===== | ||
*Prompt diagnosis of PE in COVID-19 patient is difficult in this regard that various symptoms of [[COVID-19]] overlap with that of [[pulmonary embolism]]. American Society of Hematology provides the following guidelines regarding the diagnosis of pulmonary embolism: | *Prompt diagnosis of PE in COVID-19 patient is difficult in this regard that various symptoms of [[COVID-19]] overlap with that of [[pulmonary embolism]]. American Society of Hematology provides the following guidelines regarding the diagnosis of pulmonary embolism: | ||
** Normal [[d-dimers]] level in a patient with low to moderate [[Pretest probability of DVT|pretest probability]] is sufficient to rule out the diagnosis of PE. [[D-dimers|D-dimers level]] is usually elevated in COVID-19 patients. This is not applicable to a patient with a high pretest probability. | ** Normal [[d-dimers]] level in a patient with low to moderate [[Pretest probability of DVT|pretest probability]] is sufficient to rule out the diagnosis of PE. [[D-dimers|D-dimers level]] is usually elevated in COVID-19 patients. This is not applicable to a patient with a high pretest probability. | ||
** Inpatient with suspected PE with symptoms like [[hypotension]], [[tachycardia]], and sudden drop in [[oxygen saturation]] with a high pretest probability of PE, computed [[tomography]] with [[pulmonary angiography]] is used for the diagnosis. Contraindication to the use of [[CT pulmonary angiogram|CTPA]] warrants investigation with [[Ventilation/perfusion scan|ventilation/perfusion scan.]] | ** Inpatient with suspected PE with symptoms like [[hypotension]], [[tachycardia]], and sudden drop in [[oxygen saturation]] with a high pretest probability of PE, computed [[tomography]] with [[pulmonary angiography]] is used for the diagnosis. Contraindication to the use of [[CT pulmonary angiogram|CTPA]] warrants investigation with [[Ventilation/perfusion scan|ventilation/perfusion scan.]] | ||
| Line 290: | Line 292: | ||
'''Intermediate or therapeutic dose anticoagulation''' | '''Intermediate or therapeutic dose anticoagulation''' | ||
* Drug and dose- eg, [[Enoxaparin]] 40 to 60 mg once daily | * Drug and dose- eg, [[Enoxaparin]] 40 to 60 mg once daily | ||
Indications- | Indications- | ||
*Critically ill patients or [[Intensive care unit|ICU]] patients | *Critically ill patients or [[Intensive care unit|ICU]] patients | ||
* According to a study, a better prognosis was seen in patients who met the SIC (Sepsis-induced coagulopathy) criteria or had marked elevated [[D-dimer]] levels and were put on anticoagulant therapy(mainly with [[low molecular weight heparin]]) <ref name="pmid32220112">{{cite journal| author=Tang N, Bai H, Chen X, Gong J, Li D, Sun Z| title=Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. | journal=J Thromb Haemost | year= 2020 | volume= 18 | issue= 5 | pages= 1094-1099 | pmid=32220112 | doi=10.1111/jth.14817 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32220112 }} </ref> | * According to a study, a better prognosis was seen in patients who met the SIC (Sepsis-induced coagulopathy) criteria or had marked elevated [[D-dimer]] levels and were put on anticoagulant therapy(mainly with [[low molecular weight heparin]]) <ref name="pmid32220112">{{cite journal| author=Tang N, Bai H, Chen X, Gong J, Li D, Sun Z| title=Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. | journal=J Thromb Haemost | year= 2020 | volume= 18 | issue= 5 | pages= 1094-1099 | pmid=32220112 | doi=10.1111/jth.14817 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32220112 }} </ref> | ||
| Line 303: | Line 305: | ||
'''Post-discharge thromboprophylaxis''' | '''Post-discharge thromboprophylaxis''' | ||
* Drug and dose- Regulatory-approved regimen | * Drug and dose- Regulatory-approved regimen | ||
**[[Betrixaban]] 160 mg on day 1, followed by 80 mg once daily for 35-42 days | **[[Betrixaban]] 160 mg on day 1, followed by 80 mg once daily for 35-42 days | ||
**[[Rivaroxaban]] 10 mg daily for 31-39 days | **[[Rivaroxaban]] 10 mg daily for 31-39 days | ||
Indications- | Indications- | ||
* Patients with documented [[Venous thromboembolism|VTE]] require thromboprophylaxis for up to 90 days after discharge. | * Patients with documented [[Venous thromboembolism|VTE]] require thromboprophylaxis for up to 90 days after discharge. | ||
* Some patients who do not have VTE but require extended thromboprophylaxis include- acute medical illness, older age, immobilization, recent surgery, or trauma. Most of these criteria are met by patients with COVID-19, and they require thromboprophylaxis for up to 90 days after discharge. | * Some patients who do not have VTE but require extended thromboprophylaxis include- acute medical illness, older age, immobilization, recent surgery, or trauma. Most of these criteria are met by patients with COVID-19, and they require thromboprophylaxis for up to 90 days after discharge. | ||
'''Bleeding in COVID-19''' | '''Bleeding in COVID-19''' | ||
| Line 326: | Line 328: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
<references /> | |||
Revision as of 12:40, 16 July 2020
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19-associated coagulopathy On the Web |
|
American Roentgen Ray Society Images of COVID-19-associated coagulopathy |
|
Risk calculators and risk factors for COVID-19-associated coagulopathy |
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ifrah Fatima, M.B.B.S[2]
Synonyms and keywords: Hematological findings and COVID-19, hypercoagulability in COVID-19, clotting disorder in COVID-19
Overview
Hypercoagulability is a major complication seen in as many as 31% of patients with COVID-19. It leads to many life-threatening outcomes with pulmonary embolism being the most common thrombotic complication. Fibrinogen and D-dimer levels are elevated. Coagulopathy in COVID-19 must be differentiated from other diseases that cause disseminated intravascular coagulation (DIC). Prophylactic anticoagulation with low molecular weight heparin is given to all inpatients in the absence of active bleeding. Full dose anticoagulation is done in patients with documented and confirmed venous thromboembolism (VTE) .
Historical Perspective
- The etiological agent is SARS-CoV-2, named for the similarity of its symptoms to those induced by the severe acute respiratory syndrome, causing coronavirus disease 2019 (COVID-19), is a virus identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.
- The growing number of patients however, suggest that human-to-human transmission is actively occurring.
- The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020.
- On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic.
Classification
- There is no established system for the classification of the hypercoagulability seen in COVID-19.
- The coagulopathy may be classified according to the type of vessels and organs involved into:
- To view the classification of COVID-19, click here.
Pathophysiology
- COVID-19 induces a hypercoagulable state in the body. An increased risk of mortality has been noted in patient’s with coagulopathy in COVID-19. It is thought that the coagulopathy in COVID-19 is the result of:[1]
- Virchow’s triad
- Vascular endothelial damage
- Endothelitis- direct invasion of endothelial cells by SARS-CoV-2 which exposes the vWF associated with a massive release of vWF, eventually activating the coagulation cascade.
- Complement mediated damage to pericytes
- Pro-inflammatory cytokines- IL-1, IL-6, and TNF- α, that activate the coagulation pathway and the fibrinolytic system.
- Stasis- Prolonged hospital admissions causing immobilization of the patient
- Hypercoagulabe state- Evidenced by elevated fibrinogen, prothrombotic factors and hyperviscosity
- Some patients have been found to have Lupus anticoagulant (anti-cardiolipin) and anti-β2GP1 antibodies that may be contributory.
Causes
- Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus called SARS-CoV-2 and is the cause of thrombocytopenia in COVID-19 infection.
- To view causes of COVID-19, click here.
Differentiating COVID-19 associated coagulopathy from other Diseases
- Coagulopathy in COVID-19 must be differentiated from other diseases that cause DIC which include the folowing:
- The main feature of COVID-19 coagulopathy is thrombosis while the acute phase of DIC presents with bleeding:
- Similar laboratory findings are marked increase in D-dimer and normal/slightly low platelets and prolonged PT.
- Findings distinct in COVID 19 are high fibrinogen and high factor VIII activity
- The scoring system of the International Society on Thrombosis and Hemostasis should be used to detect DIC (platelet count, PT, fibrinogen, D‐dimer, antithrombin and protein C activity monitoring), but the diagnosis and subsequent treatment should be done clinically.
To view the differential diagnosis of COVID-19, click here.
Epidemiology and Demographics
Incidence
- The incidence of venous thromboembolism in ICU patients with COVID-19 was analyzed in a study by Klok et al.
- It concluded that the cumulative incidence of acute pulmonary embolism (PE), deep vein thrombosis (DVT), ischemic stroke, MI, or systemic arterial embolism was 31%.
- The incidence of most common thrombotic complication was pulmonary embolism seen in 81% of patients. All these patients were on at least standard doses of thromboprophylaxis. [2]
- The cumulative incidence of venous thromboembolism (VTE) were 16% (95% CI, 10-22) at 7 days, 33% (95% CI, 23-43) at 14 days and 42% (95% CI 30-54) at 21 days.
- Comparatively, the cumulative incidence of venous thromboembolism (VTE) was higher in the ICU patients - 26% (95% CI, 17-37) at 7 days, 47% (95% CI, 34-58) at 14 days and 59% (95% CI, 42-72) at 21 days) than on the floor.
To view the epidemiology and demographics for COVID-19, click here.
Age
- There is insufficient information regarding age-specific prevalence or incidence of COVID-19-associated coagulopathy.
Gender
- There is insufficient information regarding gender-specific prevalence or incidence of COVID-19-associated coagulopathy.
Race
- There is insufficient information regarding race-specific prevalence or incidence of COVID-19-associated coagulopathy.
Risk Factors
Hypothesized risk factors for coagulopathy in COVID-19 pneumonia based on studies include:
Other general risk factors for venous thromboembolism (VTE) are:
To view the risk factors of COVID-19, click here.
Screening
- Every patient with COVID-19 infection admitted to the hospital should have a baseline of basic blood investigations such as
- Complete blood count (CBC)
- Platelet count
- Prothrombin Time (PT), Activated partial thromboplastin time (aPTT)
- Fibrinogen
- D-dimer
- C-reactive protein
- Routine screening with imaging is not done as there is no evidence to indicate an improvement in clinical outcomes.
- Depending on the clinical state of the patient and suspicion for the development of VTE or arterial thrombi, repeat testing and further imaging investigations are done.
To view screening for COVID-19, click here.
Natural History, Complications, and Prognosis
Natural History
- If left untreated, patients with coagulopathy may progress to develop VTE, arterial thrombosis, or microvascular thrombosis and ultimately succumb to death.
Complications
- Thrombotic complications : [1]
- Deep Vein Thrombosis
- Pulmonary Embolism
- Ischemic stroke
- Myocardial infarction
- Ischemic limbs
- Systemic arterial events
- Clotting of central venous catheters, dialysis catheters, and dialysis filters
Independent predictors of thrombotic complications seen were:
- Age
- Coagulopathy (defined as spontaneous prolongation of the prothrombin time > 3 s or activated partial thromboplastin time > 5 s)
- Active cancer
Prognosis
Prognosis depends on numerous factors-
- Increased D-dimer levels- poor prognosis
- Increased fibrin degradation product (FDP) levels [3]
- ICU admission
To view natural history, complications, and prognosis of COVID-19, click here.
Diagnosis
Diagnostic Study of Choice
- The diagnosis of coagulopathy in COVID-19 is based mainly on the laboratory findings showing a pro-coagulant profile.
- The pre-test probability of DVT and PE can be calculated using the Wells' criteria
- Computed Tomography with pulmonary angiography (CTPA) is the diagnostic test of choice. Ventilation/Perfusion scan may also be done, but may not be of much yield in patients with COVID-19.
- To view the study of choice for diagnosis of COVID-19, click here.
History and Symptoms
The symptoms depend on the vessels and the organ systems involved.
Pulmonary Embolism- Many symptoms of PE overlap with the respiratory symptoms seen in COVID-19.
- Maybe asymptomatic
- Dyspnea
- Chest pain
- Cough
- Some other rare presentations include- hemoptysis, shock, hypotension, death.
A positive history of the following is suggestive of and contributory-
- Immobilization or prolonged hospitalization
- Recent surgery
- Trauma
- Obesity
- History of previous venous thromboembolism (VTE)
- Malignancy
- Stroke with hemiplegia or immobility
- Age >65 years
Deep Vein Thrombosis
Arterial thrombosis involving various systems show the following symptoms:
- Ischemic Stroke: various focal neurological deficits depending on the large artery involved
- Myocardial infarction: Chest pain radiating to left arm and neck, sweating, dyspnea
- Acute ischemic limb: pain, pallor, poikilothermia, pulselessness, paresthesia, paralysis
To view the history and symptoms of COVID-19, click here.
Physical Examination
Pulmonary Embolism Physical examination of patients with Pulmonary Embolism is usually remarkable for-
Deep Vein Thrombosis Physical examination of patients with Deep Vein Thrombosis includes-
- Unilateral swelling/edema with a difference in diameters
- Warmth
- Tenderness
- Dilated veins
- Homan's sign may also be seen but is unreliable.
Arterial thrombosis-
- Ischemic Stroke- Focal neurological deficits depending on the vessel involved
- Myocardial Infarction- uncomfortable appearing patient with diaphoresis
- Ischemic Limb- pallor, poikilothermia, pulselessness, paresthesia, paralysis
To view the complete physical examination in COVID-19, click here.
Laboratory Findings
An elevated concentration of serum/blood pro-coagulant factors is diagnostic of coagulopathy associated with COVID-19. Laboratory findings consistent with the diagnosis of COVID-19 associated coagulopathy include:
- Coagulation testing- Pro-coagulant profile
- Platelet Counts- Normal or increased
- Prothrombin time (PT) and activated partial thromboplastin time (aPTT)- normal or slightly prolonged
- Fibrinogen- increased
- D-dimer- increased
- Factor VIII activity- increased
- VWF antigen- increased
- Protein C, Protein S, Antithrombin III - slightly decreased
TEG findings:
- Reaction time (R) - decreased
- Clot formation time (K)- decreased
- Maximum amplitude (MA)- increased
- Clot lysis at 30 minutes (LY30)- decreased
To view the laboratory findings on COVID-19, click here.
Electrocardiogram
An ECG may be helpful in the diagnosis of pulmonary embolism or myocardial infacrctioncaused due to hypercoagulability in COVID-19.
- Findings on an ECG suggestive of/diagnostic of pulmonary embolism include tachycardia and S1Q3T3 pattern.
- Findings on an ECG suggestive of/diagnostic of myocardial infarction include STE elevation in various leads.
- To view the electrocardiogram findings on COVID-19, click here.
X-ray
There are no specific x-ray findings associated with PE. However, an x-ray may be helpful in ruling out other causes with similar symptoms like pneumonia, cardiogenic causes of dyspnea, and pneumothorax.
- To view the x-ray finidings on COVID-19, click here.
Echocardiography or Ultrasound
- Echocardiography may be helpful in the diagnosis of pulmonary embolism.
- Compressive Ultrasound may be helpful in the diagnosis of deep vein thrombosis
- To view the echocardiographic findings on COVID-19, click here.
CT scan
CTPA and Ventilation Perfusion(V/Q) Scan
- Prompt diagnosis of PE in COVID-19 patient is difficult in this regard that various symptoms of COVID-19 overlap with that of pulmonary embolism. American Society of Hematology provides the following guidelines regarding the diagnosis of pulmonary embolism:
- Normal d-dimers level in a patient with low to moderate pretest probability is sufficient to rule out the diagnosis of PE. D-dimers level is usually elevated in COVID-19 patients. This is not applicable to a patient with a high pretest probability.
- Inpatient with suspected PE with symptoms like hypotension, tachycardia, and sudden drop in oxygen saturation with a high pretest probability of PE, computed tomography with pulmonary angiography is used for the diagnosis. Contraindication to the use of CTPA warrants investigation with ventilation/perfusion scan.
To view the CT scan findings on COVID-19, click here.
MRI
- There are no MRI findings associated with coagulopathy of COVID-19 unless it is used to diagnose and evaluate an ischemic stroke caused by it.
- To view the MRI findings on COVID-19, click here.
Other Imaging Findings
There are no other imaging findings associated with coagulopathy of COVID-19
Other Diagnostic Studies
- To view other diagnostic studies for COVID-19, click here.
Treatment
Medical Therapy
Prophylactic dose of anticoagulation
- Drug- LMWH is preferred over unfractionated heparin to reduce contact with the patient. Unfractionated heparin may be used in case of unavailability or severe renal impairment.
Indications-
- All inpatients in the absence of active bleeding
- To be held only if platelet counts fall below 25 x 109/L, or fibrinogen less than 0.5 g/L
- In case of a history of heparin-induced thrombocytopenia(HIT), fondaparinux is used.
Intermediate or therapeutic dose anticoagulation
- Drug and dose- eg, Enoxaparin 40 to 60 mg once daily
Indications-
- Critically ill patients or ICU patients
- According to a study, a better prognosis was seen in patients who met the SIC (Sepsis-induced coagulopathy) criteria or had marked elevated D-dimer levels and were put on anticoagulant therapy(mainly with low molecular weight heparin) [5]
Therapeutic/ full-dose anticoagulation
- Drug and dose- eg, enoxaparin 1 mg/kg every 12 hours
Indications-
- Suspected VTE/PE
- Confirmed VTE/PE
- Clotting in catheters, or extracorporeal circuits like ECMO and CRRT. [6]
Post-discharge thromboprophylaxis
- Drug and dose- Regulatory-approved regimen
- Betrixaban 160 mg on day 1, followed by 80 mg once daily for 35-42 days
- Rivaroxaban 10 mg daily for 31-39 days
Indications-
- Patients with documented VTE require thromboprophylaxis for up to 90 days after discharge.
- Some patients who do not have VTE but require extended thromboprophylaxis include- acute medical illness, older age, immobilization, recent surgery, or trauma. Most of these criteria are met by patients with COVID-19, and they require thromboprophylaxis for up to 90 days after discharge.
Bleeding in COVID-19
- Transfusion and replacement; discontinuation or reversal of anticoagulation are the mainstay of treatment
- Transfuse platelets if the platelet count is less than 50 x 109/L
- Administer plasma if the INR is above 1.8
- Order fibrinogen concentrate or cryoprecipitate if the fibrinogen level is less than 1.5 g/L
- To view medical treatment for COVID-19, click here.
References
- ↑ 1.0 1.1 Becker RC (2020). "COVID-19 update: Covid-19-associated coagulopathy". J Thromb Thrombolysis. doi:10.1007/s11239-020-02134-3. PMC 7225095 Check
|pmc=value (help). PMID 32415579 Check|pmid=value (help). - ↑ 2.0 2.1 Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM; et al. (2020). "Incidence of thrombotic complications in critically ill ICU patients with COVID-19". Thromb Res. 191: 145–147. doi:10.1016/j.thromres.2020.04.013. PMC 7146714 Check
|pmc=value (help). PMID 32291094 Check|pmid=value (help). - ↑ Tang N, Li D, Wang X, Sun Z (2020). "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia". J Thromb Haemost. 18 (4): 844–847. doi:10.1111/jth.14768. PMC 7166509 Check
|pmc=value (help). PMID 32073213 Check|pmid=value (help). - ↑ "COVID-19 pneumonia and pulmonary emboli | Radiology Case | Radiopaedia.org".
- ↑ Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020). "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy". J Thromb Haemost. 18 (5): 1094–1099. doi:10.1111/jth.14817. PMID 32220112 Check
|pmid=value (help). - ↑ Akima S, McLintock C, Hunt BJ (2020). "RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19". J Thromb Haemost. doi:10.1111/jth.14853. PMID 32302442 Check
|pmid=value (help).